Grappling with allegations of improper sales practices, Alexion Pharmaceuticals has announced a failure of a Phase II/III trial for expanded use of Soliris.
In the wake of a failed Phase IIb clinical trial, Opexa Therapeutics announced it will be laying off about 40 percent of its workforce.
Robert Mulroy, CEO of Merrimack Pharmaceuticals, has resigned his position as part of a corporate restructuring move that will result in a 22 percent workforce reduction.
April 25, 2016 By Alex Keown, BioSpace.com Breaking News Staff DUBLIN — John T. Hendrickson has been tapped as the new chief executive officer of Perrigo Company PLC (PRGO), after former CEO Joseph Papa left the company to helm rival Valeant Pharmaceuticals (VRX). Last week BioSpace (DHX) reported Papa was the favorite to […]
BOIULDER, Colo. – After three months on the job, Array BioPharma, Inc. (ARRY)’s Chief Financial Officer Patricia Henahan is resigning her position, the company disclosed in a federal filing. Henahan’s last day is set for Dec. 17, four months and nine days after assuming her post with the company. Array disclosed the job change in […]